Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Taysha Gene Therapies, Inc. reported revenue of $10M, up 17.3% year over year. Operating margin was -1130.6% and net margin -1115.3%, on a free-cash-flow margin of -960.1% with capital expenditure at 7.6% of revenue. Every figure is computed directly from TSHA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $10M | -1130.6% | -1115.3% |
| FY2024 | $8M | -1097.6% | -1071.6% |
| FY2023 | $15M | -468.8% | -722.1% |
| FY2022 | $3M | -6492.7% | -6635.3% |
| FY2021 | n/a | n/a | n/a |
How does TSHA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.